MDR Requirements for Sponsor GCP Inspections (audits) and How to Conduct Them
45 Min
1 Lesson
Price
Free
Lecturer
Maria Donawa
Member of the Board, EAAR, President, Donawa Lifescience, Italy
Maria E. Donawa, MD is President, Donawa Lifescience, headquartered in Rome, Italy, with over 30 years’ regulatory experience, including six years with the US FDA, in the area of medical device regulation. Donawa Lifescience provides US and European quality system, regulatory and clinical services to life science companies worldwide.
Dr Donawa is an active member of the ISO study group responsible for the development and revision of ISO 14155, the international standard for medical device clinical investigations.
She is also a stakeholder observer to the Clinical Investigation and Evaluation (CIE) Working Group. The CIE assists the Medical Device Coordination Group (MDCG) on issues relating to clinical investigation and evaluation of medical devices in accordance with the MDR.
Dr Donawa has US degrees in pharmacy and medicine, with post-doctoral specialization in clinical and anatomical pathology.
Dr Donawa is an active member of the ISO study group responsible for the development and revision of ISO 14155, the international standard for medical device clinical investigations.
She is also a stakeholder observer to the Clinical Investigation and Evaluation (CIE) Working Group. The CIE assists the Medical Device Coordination Group (MDCG) on issues relating to clinical investigation and evaluation of medical devices in accordance with the MDR.
Dr Donawa has US degrees in pharmacy and medicine, with post-doctoral specialization in clinical and anatomical pathology.
Description
Sponsors of clinical investigations planned to be conducted under the MDR will need to comply with a new requirement to “provide evidence that the investigation is being conducted in line with good clinical practice (GCP), for instance through internal or external inspection.” The previous MDD and AIMDD do not include such a requirement. Such an audit activity has been described previously, very briefly in EN ISO 14155-1:2003, and in somewhat more detail in EN ISO 14155:2011. EN ISO 14155:2020, however, includes a new informative Annex on clinical investigation audits, which provides general guidance on the areas that should be checked during the audit. This presentation will discuss the guidance on GCP audits in EN ISO 14155:2020 and provide practical advice on the organization, conduct and documentation of the audit process.
Related Courses
Competent Authority Update on Preparing for IVDR Clinical Performance Study Applications
Nebojsa Serafimovic
BASG - Austrian Federal Office…
29 Min
1 Lesson
Free
Critical Considerations in Site Selection and Subject Enrollment in Device and IVD Clinical Studies
Matteo Mosso
Donawa Lifescience, Italy
34 Min
1 Lesson
Free
Competent Authority Expectations and Management of Device Clinical Study Applications Under the MDR
Tom Melvin
Health Products Regulatory Authority (HPRA),…
22 Min
1 Lesson
Free
Developing Clinical Investigation and Performance Study Plans That Meet Regulatory and Operational Requirements
Daniela Karrer
Donawa Lifescience, Italy
46 Min
1 Lesson
Free
